Injectable Fillers and Botulinum Toxin — MCQs
Which class of drugs does botulinum toxin mimic in its action?
What condition is suggested by eyelid papules and a hoarse cry in a child?
Mechanism of action of d-tubocurarine is:
What type of graft or dressing is used to cover the post-burn wound shown in the image?
The mechanism of action of botulinum toxin A is best described by:
Which of the following is a common topical use of the medicine shown in the image?
A 40-year-old woman with severe tension headaches presents after failing medical therapy. What is the most appropriate next step in management?
Loss of lateral 1/3rd of eyebrow is seen in -
Botulinum toxin is used in -
Exocytic release of acetylcholine is blocked by
Injectable Fillers and Botulinum Toxin Indian Medical PG Practice Questions and MCQs
Question 1: Which class of drugs does botulinum toxin mimic in its action?
- A. Adrenergics
- B. Antiadrenergic
- C. Cholinergics
- D. Anticholinergics (Correct Answer)
Explanation: ***Anticholinergics*** - **Botulinum toxin** inhibits the release of **acetylcholine** from **presynaptic nerve terminals** [2] by preventing vesicle fusion, leading to muscle paralysis [1]. - While the **mechanism differs** (botulinum acts presynaptically, anticholinergics act postsynaptically at receptors), the **functional outcome** is similar: reduced cholinergic neurotransmission. - In terms of **clinical effect** at the neuromuscular junction, both reduce acetylcholine's action, making anticholinergics the closest functional parallel among the given options. *Cholinergics* - **Cholinergics** enhance acetylcholine activity, either by increasing its release, mimicking its effects at receptors, or inhibiting its breakdown. - This is the **opposite** of botulinum toxin's action, which reduces acetylcholine's impact. *Adrenergics* - **Adrenergics** stimulate the **sympathetic nervous system** via **adrenergic receptors** (α and β receptors). - They act on **norepinephrine/epinephrine pathways**, not the cholinergic system where botulinum toxin acts. *Antiadrenergic* - **Antiadrenergic drugs** block **adrenergic receptors** or inhibit sympathetic activity. - These are unrelated to botulinum toxin's effect on **cholinergic neuromuscular transmission**.
Question 2: What condition is suggested by eyelid papules and a hoarse cry in a child?
- A. Croup
- B. Lipoid proteinosis (Correct Answer)
- C. Acrodermatitis enteropathica
- D. Congenital syphilis
Explanation: ***Lipoid proteinosis*** - This condition is characterized by **hoarseness from infancy** due to deposition in the vocal cords and characteristic **beaded papules on the eyelids** (moniliform blepharosis). - Also known as **Urbach-Wiethe disease**, it is a rare autosomal recessive disorder resulting from mutations in the **ECM1 gene**, leading to abnormal deposition of hyaline material in various tissues. *Croup* - Croup typically presents with a **barking cough** and **stridor**, often following a viral upper respiratory infection. - It does not cause eyelid papules or chronic hoarseness from infancy, but rather acute respiratory distress. *Acrodermatitis enteropathica* - This is a rare autosomal recessive disorder of **zinc malabsorption**, leading to a classic triad of **dermatitis**, **diarrhea**, and **alopecia**. - It does not involve eyelid papules or hoarseness as primary features. *Congenital syphilis* - Congenital syphilis can cause a wide range of manifestations, including skin rashes, bone abnormalities, and rhinitis ("snuffles"), but eyelid papules and chronic hoarseness are not typical presenting features. - Diagnosis is usually confirmed by serological tests for syphilis.
Question 3: Mechanism of action of d-tubocurarine is:
- A. Competitive, nondepolarizing block at the Nm cholinergic receptor (Correct Answer)
- B. Noncompetitive, depolarizing block at the Nm cholinergic receptor
- C. Non-competitive, nondepolarizing block at the Nm cholinergic receptor
- D. Competitive, depolarizing block at the Nm cholinergic receptor
Explanation: ***Competitive, nondepolarizing block at the Nm cholinergic receptor*** - **d-tubocurarine** acts as a **competitive antagonist** at the **nicotinic muscle (Nm) cholinergic receptors** on the motor endplate. - It competes with **acetylcholine (ACh)** for binding sites, preventing ACh from activating the receptor and causing **muscle paralysis** without depolarization. *Noncompetitive, depolarizing block at the Nm cholinergic receptor* - This describes the mechanism of action of **depolarizing neuromuscular blockers** like **succinylcholine**, which first *depolarize* the motor endplate before causing paralysis. - d-tubocurarine does not cause initial depolarization; it directly blocks the receptor. *Non-competitive, nondepolarizing block at the Nm cholinergic receptor* - While d-tubocurarine is **nondepolarizing**, it is a **competitive antagonist**, not a non-competitive one. - A non-competitive block would involve binding to a different site on the receptor or an associated ion channel, altering receptor function indirectly. *Competitive, depolarizing block at the Nm cholinergic receptor* - This option incorrectly combines the concepts, as **depolarizing blockers** like succinylcholine act initially by **depolarizing** the endplate, whereas d-tubocurarine is purely a **nondepolarizing** agent. - The "competitive" aspect would be true for the binding of ACh to its site on a depolarizing agent, but the effect of d-tubocurarine is simply to block, not depolarize.
Question 4: What type of graft or dressing is used to cover the post-burn wound shown in the image?
- A. Split thickness skin graft (Correct Answer)
- B. Full thickness skin graft
- C. VAC dressing
- D. Normal saline dressing
Explanation: ***Split thickness skin graft*** - The image shows a **meshed pattern** on the skin graft, which is characteristic of a **split-thickness skin graft** that has been expanded to cover a larger area. - This type of graft consists of the epidermis and a portion of the dermis, making it more flexible and able to **"take" more reliably** on various wound beds, commonly used for burn wounds. *Full thickness skin graft* - A **full-thickness skin graft** includes the entire epidermis and dermis and typically does not have a meshed appearance. - They are used for smaller defects where cosmesis is a priority, but have a **lower take rate** than split-thickness grafts, making them less suitable for large burn wounds. *VAC dressing* - A **VAC (Vacuum-Assisted Closure) dressing** is a system that applies negative pressure to a wound to promote healing and is not a skin graft itself. - It involves a foam or gauze dressing sealed with an adhesive film, connected to a vacuum pump, which is not what is depicted in the image. *Normal saline dressing* - A **normal saline dressing** is a simple wet-to-dry or wet-to-wet dressing for wound care, involving gauze soaked in normal saline. - This is a basic wound management technique and does not involve grafting or have the characteristic meshed appearance seen in the image.
Question 5: The mechanism of action of botulinum toxin A is best described by:
- A. Slowing of myelinated nerve fiber transmission
- B. Postsynaptic receptor blockade
- C. Acetylcholinesterase inhibition
- D. Presynaptic blockade of acetylcholine release (Correct Answer)
Explanation: ***Presynaptic blockade of acetylcholine release*** - **Botulinum toxin A** acts by cleaving specific proteins (**SNARE proteins** like SNAP-25, synaptobrevin, and syntaxin) essential for the fusion of **acetylcholine-containing vesicles** with the presynaptic membrane. - This prevents the release of acetylcholine into the **neuromuscular junction**, leading to muscle paralysis. *Slowing of myelinated nerve fiber transmission* - This describes the action of agents that affect **myelin sheaths** (e.g., demyelinating diseases) or ion channels involved in action potential propagation, not the mechanism of botulinum toxin. - Botulinum toxin specifically targets the **synaptic transmission**, not the speed of nerve conduction itself. *Postsynaptic receptor blockade* - This mechanism is seen with drugs like **curare** or **neuromuscular blockers** (e.g., rocuronium, vecuronium), which compete with acetylcholine for binding to **nicotinic acetylcholine receptors** on the muscle endplate. - Botulinum toxin does not affect the postsynaptic receptors directly; its action is entirely presynaptic. *Acetylcholinesterase inhibition* - **Acetylcholinesterase inhibitors** (e.g., neostigmine, pyridostigmine) prevent the breakdown of acetylcholine in the synaptic cleft, increasing its concentration and prolonging its action. - This mechanism would enhance, rather than block, muscle contraction, which is opposite to the effect of botulinum toxin.
Question 6: Which of the following is a common topical use of the medicine shown in the image?
- A. Rhino cerebral mucormycosis
- B. Inlay type I myringoplasty
- C. Post-adenoidectomy to control bleeding (Correct Answer)
- D. Subglottic stenosis
Explanation: ***Post-adenoidectomy to control bleeding*** - The image shows **Neo-Synephrine (phenylephrine)**, a potent **alpha-adrenergic agonist** that causes **vasoconstriction**. - Its vasoconstrictive properties make it useful topically to reduce **bleeding** during and after surgical procedures like **adenoidectomy**. *Rhino cerebral mucormycosis* - This is a serious fungal infection requiring systemic antifungal therapy, often **amphotericin B**. Topical phenylephrine has no role in treating the infection itself. - While bleeding might be a symptom of mucormycosis, phenylephrine would only offer temporary symptomatic relief, not address the underlying fungal pathology. *Inlay type I myringoplasty* - Myringoplasty is a surgical procedure to repair a perforated eardrum. Topical phenylephrine is not indicated for this procedure. - The primary goal of this surgery is to reconstruct the **tympanic membrane**, and phenylephrine would not contribute to tissue healing or graft integration. *Subglottic stenosis* - This condition involves narrowing of the airway below the vocal cords, often requiring surgical intervention or corticosteroids. - Phenylephrine is a decongestant and vasoconstrictor, and as such, it does not have a therapeutic role in resolving the **fibrotic narrowing** characteristic of subglottic stenosis.
Question 7: A 40-year-old woman with severe tension headaches presents after failing medical therapy. What is the most appropriate next step in management?
- A. Opioid analgesics
- B. Nerve decompression surgery
- C. Botox injections for chronic tension-type headaches
- D. Cognitive behavioral therapy (Correct Answer)
Explanation: ***Cognitive behavioral therapy*** - **CBT** has strong evidence as **primary therapy** for chronic tension-type headaches failing medical management, helping patients develop coping strategies and modify pain-related behaviors. - It can significantly **reduce headache frequency and intensity** in tension-type headaches by addressing psychological triggers, stress management, and muscle tension patterns. *Opioid analgesics* - **Opioid analgesics** are generally **contraindicated** for chronic headache management due to the significant risks of **medication overuse headache (MOH)**, dependence, tolerance, and other side effects [1]. - They provide only temporary relief and can worsen headache prognosis over time, making them an inappropriate long-term strategy, especially after failing other therapies [1]. *Nerve decompression surgery* - **Nerve decompression surgery** (e.g., occipital nerve decompression) is a **highly specialized** and **invasive** procedure for very specific types of refractory headaches, such as occipital neuralgia or certain chronic migraines. - It is typically considered only after **all other conservative and less invasive medical and interventional therapies** have failed, and after thorough diagnostic workup to confirm a surgically amenable nerve entrapment. *Botox injections for chronic tension-type headaches* - **OnabotulinumtoxinA (Botox)** is FDA-approved specifically for **chronic migraine**, not for tension-type headaches, making it inappropriate for this clinical scenario. - Off-label use would not constitute the **"most appropriate next step"** when evidence-based treatments like CBT exist specifically for tension-type headaches.
Question 8: Loss of lateral 1/3rd of eyebrow is seen in -
- A. Tetanus
- B. Tinea capitis
- C. Lepromatous leprosy (Correct Answer)
- D. Tuberculosis
Explanation: ***Lepromatous leprosy*** - **Loss of the lateral one-third of the eyebrow** (also known as **madarosis**) is a characteristic feature of **lepromatous leprosy** due to chronic inflammation and nerve damage affecting hair follicles. - This, along with diffuse skin infiltration and nodule formation, is part of the typical presentation of the **multibacillary form** of the disease. *Tetanus* - Tetanus is characterized by **muscle spasms** and **lockjaw** due to the action of tetanus toxin on inhibitory neurotransmitters. - It does not cause hair loss or specific dermatological lesions like eyebrow loss. *Tinea capitis* - Tinea capitis is a **fungal infection of the scalp** that causes scaling, itching, and patchy hair loss on the head. - It does not typically affect the eyebrows or cause isolated loss of the lateral one-third part. *Tuberculosis* - Tuberculosis primarily affects the **lungs** but can manifest in various extrapulmonary sites. - While systemic symptoms and skin lesions (e.g., **lupus vulgaris**) can occur, **eyebrow loss** is not a characteristic feature of tuberculosis.
Question 9: Botulinum toxin is used in -
- A. Myasthenia gravis
- B. Cerebellar ataxia
- C. Focal dystonia (Correct Answer)
- D. Hypotonia
Explanation: ***Focal dystonia*** - **Botulinum toxin** is a potent neurotoxin that relaxes muscles by blocking the release of **acetylcholine** at the neuromuscular junction. - In **focal dystonia**, specific muscles contract involuntarily, causing abnormal postures or movements; botulinum toxin injections can temporarily paralyze these muscles, reducing symptoms. *Myasthenia gravis* - **Myasthenia gravis** is an **autoimmune disease** characterized by muscle weakness due to antibodies blocking **acetylcholine receptors** at the neuromuscular junction. - Injecting **botulinum toxin** would further weaken the already compromised muscles, exacerbating the condition, and is therefore contraindicated. *Cerebellar ataxia* - **Cerebellar ataxia** results from damage to the **cerebellum**, leading to problems with coordination, balance, and fine motor control. - **Botulinum toxin** acts on the neuromuscular junction and would not address the underlying neurological deficit in the cerebellum. *Hypotonia* - **Hypotonia** refers to decreased muscle tone, often caused by problems in the brain, spinal cord, nerves, or muscles. - Using **botulinum toxin**, which causes muscle paralysis, would worsen **hypotonia** by further reducing muscle tone and strength.
Question 10: Exocytic release of acetylcholine is blocked by
- A. Hemicholinium (inhibits choline reuptake)
- B. Alphabungarotoxin (blocks ACh at receptors)
- C. Vesamicol (interferes with ACh loading)
- D. Botulinum toxin (blocks release of ACh) (Correct Answer)
Explanation: ***Botulinum toxin (blocks release of ACh)*** - **Botulinum toxin** acts by cleaving SNARE proteins (SNAP-25, synaptobrevin, syntaxin) which are essential for the fusion of synaptic vesicles with the presynaptic membrane, thereby **blocking exocytic release of acetylcholine**. - This blockage prevents the release of neurotransmitter from the nerve terminal, leading to muscle paralysis or reduced glandular secretions. *Hemicholinium (inhibits choline reuptake)* - **Hemicholinium** inhibits the high-affinity reuptake of **choline** into the presynaptic neuron, which is a crucial step in the synthesis of acetylcholine. - While it depletes acetylcholine stores over time, it does not directly block the immediate exocytic release of already synthesized acetylcholine. *Alphabungarotoxin (blocks ACh at receptors)* - **Alpha-bungarotoxin** is a potent antagonist that binds irreversibly and competitively to **nicotinic acetylcholine receptors (nAChR)** on the postsynaptic membrane. - Its action is postsynaptic, meaning it blocks the effect of acetylcholine once released, rather than preventing its release from the presynaptic terminal. *Vesamicol (interferes with ACh loading)* - **Vesamicol** inhibits the **vesicular acetylcholine transporter (VAChT)**, which is responsible for loading newly synthesized acetylcholine into synaptic vesicles. - By preventing the packaging of acetylcholine into vesicles, vesamicol reduces the amount of neurotransmitter available for release, but it does not directly block the exocytosis mechanism itself.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free